Needham stays Buy on Artivion Inc. (AORT) amid NEXUS FDA approval
Tweet Send to a Friend
Needham analyst Mike Matson reiterated a Buy rating and $58.00 price target on Artivion Inc. (NYSE: AORT)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
